Current Headlines

  1. C4XD Lends Its NMR Technology To Takeda For 3D Drug Molecule Structures
    8/28/2014

    C4X Discovery (C4XD) announced in a press release that it will lend its Nuclear Magnetic Resonance (NMR) technology to Takeda Cambridge Limited (TCB). The new partners seek to use the technology to make 3D identifications of TCB’s drug molecules. Piers Morgan, CEO of C4XD, said, "We are delighted to partner with TCB, a leading pharma company with world class target identification and validation capabilities. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD's technology."

  2. Antitope To Partner With UCL In Antibody Project
    8/27/2014

    Antitope, an Abzena firm focused on biopharmaceutical development, announced its collaboration with the University College London (UCL) to humanize an anti-LRG1 antibody in order to inhibit cancer growth and spread.

  3. Alexion Launches Eculizumab Trial In Kidney Transplant DGF
    8/27/2014

    Alexion announced that it has started dosing in its clinical trial evaluating eculizumab for the prevention of delayed graft function (DGF). The trial involves adult patients who have undergone kidney transplantation and who are at increased risk of DGF.

  4. Alkermes Submits NDA For New Schizophrenia Drug
    8/27/2014

    Alkermes yesterday announced its submission of a New Drug Application (NDA) to the U.S. FDA for its much awaited schizophrenia drug, aripiprazole lauroxil. The drug is a long-acting injectable atypical antipsychotic, which if approved, will be a novel once-monthly treatment for schizophrenia.

  5. DPx Holdings B.V. Reaches Definitive Agreement To Acquire Gallus BioPharmaceuticals
    8/27/2014

    DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners. Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.

  6. American Airlines Cargo Begins Work On State-Of-The-Art Pharmaceutical Facility In Philadelphia
    8/26/2014

    American Airlines Cargo has started construction of a dedicated pharmaceutical handling facility in Philadelphia, PA.

  7. Scientists Turn To Pomegranate To Develop Dementia Drugs
    8/26/2014

    Scientists from the University of Huddersfield reported that dementia and neuro-inflammation may be curbed by a natural compound found in pomegranate.

  8. Emergent And MorphoSys To Co-Develop Prostate Cancer Drug
    8/26/2014

    Emergent BioSolutions announced that it has signed an agreement with therapeutic antibody specialist firm MorphoSys to co-develop and commercialize its preclinical bi-specific antibody ES414 as treatment for prostate cancer.

  9. Insys Therapeutics’ Cannabidiol Granted Another Orphan Drug Designation
    8/26/2014

    Insys Therapeutics announced that the FDA has granted another orphan drug designation (ODD) for its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), a common and aggressive form of malignant brain tumor. This is the second such designation for Insys’ CBD and the third for cannabis-based pharmaceuticals.

  10. Miriam Monge To Join Sartorius Stedim Biotech As Director Of Marketing For Integrated Solutions
    8/26/2014

    Sartorius Stedim Biotech (SSB), a leading international pharma and biotech supplier, today announced the appointment of Miriam Monge as Director of Marketing for SSB’s Integrated Solutions unit.